Zhang Tianyu, Lin Zhili, Zheng Ziwei, Wang Quanqiang, Zhou Shujuan, Zhang Bingxin, Zheng Dong, Chen Zixing, Zheng Sisi, Zhang Yu, Lin Xuanru, Dong Rujiao, Chen Jingjing, Qian Honglan, Hu Xudong, Zhuang Yan, Zhang Qianying, Jin Zhouxiang, Jiang Songfu, Ma Yongyong
Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Department of Neurology, The First People's Hospital of Fuyang District, Hangzhou, Zhejiang, China.
Front Oncol. 2024 Mar 18;14:1322680. doi: 10.3389/fonc.2024.1322680. eCollection 2024.
To assess the prognostic significance of β2-microglobulin decline index (β2M DI) in multiple myeloma (MM).
150 MM patients diagnosed with MM were enrolled in this study. Cox proportional hazards model was used to analyze the uni- and multivariate prognosis in training cohort (n=105). A new combined prognostic model containing β2M DI was built up based on the data in training cohort. The validation group was used to verify the model.
β2M DI showed significant correlation with prognosis in both uni- and multivariate analyses and had a good correlation with complete response (CR) rate and deep remission rate. The ROC and calibration curves in validation cohort (n=45) indicated a good predictive performance of the new model. Based on the median risk score of the training group, we classified patients into high- and low- risk groups. In both training and validation groups, patients in the low-risk group had longer overall survival (OS) time than that in the high-risk group (p<0.05).
β2M DI is a good predictive index for predicting treatment response and survival time in MM patients. The prognostic model added with β2M DI showed a better correlation with OS.
评估β2微球蛋白下降指数（β2M DI）在多发性骨髓瘤（MM）中的预后意义。
本研究纳入150例确诊为MM的患者。采用Cox比例风险模型分析训练队列（n = 105）中的单因素和多因素预后情况。基于训练队列中的数据建立了一个包含β2M DI的新的联合预后模型。使用验证组对该模型进行验证。
在单因素和多因素分析中，β2M DI均与预后显著相关，且与完全缓解（CR）率和深度缓解率具有良好的相关性。验证队列（n = 45）中的ROC曲线和校准曲线表明新模型具有良好的预测性能。根据训练组的中位风险评分，将患者分为高风险组和低风险组。在训练组和验证组中，低风险组患者的总生存期（OS）均长于高风险组患者（p<0.05）。
β2M DI是预测MM患者治疗反应和生存时间的良好指标。加入β2M DI的预后模型与OS具有更好的相关性。
